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expression of recombinant 
glutamic acid decarboxylase in 
insect larvae and its application in 
an immunoassay for the diagnosis 
of autoimmune diabetes mellitus
Aldana trabucchi1,2, Silvina S. Bombicino1,2, Alexandra M. targovnik3,4, Juan I. Marfía1,2, 
Adriana V. sabljic1,2, Natalia I. Faccinetti1,2, Luciano L. Guerra1,2, Ruben F. Iacono1,2, 
María V. Miranda3,4 & Silvina N. Valdez1,2
Autoimmune Diabetes Mellitus (DM) is a chronic disease caused by the selective destruction of insulin 
producing beta cells in human pancreas. DM is characterized by the presence of autoantibodies that 
bind a variety of islet-cell antigens. The 65 kDa isoform of glutamate decarboxylase (GAD65) is a major 
autoantigen recognized by these autoantibodies. Autoantibodies to GAD65 (GADA) are considered 
predictive markers of the disease when tested in combination with other specific autoantibodies. In 
order to produce reliable immunochemical tests for large scale screening of autoimmune DM, large 
amounts of properly folded GAD65 are needed. Herein, we report the production of human GAD65 
using the baculovirus expression system in two species of larvae, Rachiplusia nu and Spodoptera 
frugiperda. GAD65 was identified at the expected molecular weight, properly expressed with high yield 
and purity in both larvae species and presenting appropriate enzymatic activity. The immunochemical 
ability of recombinant GAD65 obtained from both larvae to compete with [35S]GAD65 was assessed 
qualitatively by incubating GADA-positive patients’ sera in the presence of 1 μM of the recombinant 
enzyme. All sera tested became virtually negative after incubation with antigen excess. Besides, 
radiometric quantitative competition assays with GADA-positive patients’ sera were performed by 
adding recombinant GAD65 (0.62 nM–1.4 µM). All dose response curves showed immunochemical 
identity between proteins. In addition, a bridge-ELISA for the detection of GADA was developed using 
S. frugiperda-GAD65. This assay proved to have 77.3% sensitivity and 98.2% of specificity. GAD65 could 
be expressed in insect larvae, being S. frugiperda the best choice due to its high yield and purity. The 
development of a cost effective immunoassay for the detection of GADA was also afforded.
Type 1 Diabetes Mellitus (T1DM) is a widespread disease that may lead to the development of severe clinical con-
ditions, such as ketoacidosis, retinopathy, neuropathy, nephropathy and death due to severe metabolic imbalance. 
The global incidence of T1DM is increasing by approximately 3% per year, with patients requiring life-long insu-
lin replacement therapy1. T1DM is a chronic disease caused by the selective destruction of insulin producing beta 
cells of the pancreas, mediated by a clinically silent autoimmune process2,3. Both humoral and cellular immune 
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responses are associated with T1DM, with autoantibodies that bind a variety of islet-cell antigens. Current diabe-
tes studies are focused on the prediction and prevention of insulin deficiency in T1DM. To that end, large-scale 
screening for autoantibodies must be carried out.
A major autoantigen recognized by these autoantibodies is an islet-cell protein identified as the 65 kDa iso-
form of glutamic acid decarboxylase (GAD65). This enzyme catalyzes the decarboxylation of glutamic acid to 
γ-aminobutyric acid (GABA) and CO24–8. Autoantibodies to GAD65 (GADA) are a valuable humoral marker that 
can be used both to classify and monitor the progression of the disease9. The other autoantibodies present in auto-
immune DM are: insulin/proinsulin autoantibodies (IAA/PAA), insulinoma-associated tyrosine phosphatase 2 
autoantibodies (IA-2A) and zinc transporter isoform 8 autoantibodies (ZnT8A). When assay thresholds for IAA/
PAA, GADA, IA-2A and ZnT8A are set at the 99th percentile of controls, approximately 98% of children with 
new-onset diabetes are found to express at least one of these autoantibodies10. In addition, GADA are considered 
predictive markers when tested in combination with other disease-specific autoantibodies11, such as those of 
autoimmune tyroid disease, celiac disease, Addison’s disease and vitiligo12.
Therefore, in order to produce reliable immunochemical tests for large scale screening of population deemed 
at risk due to a family history of autoimmune diabetes, and/or other genetic factors, large amounts of properly 
folded human GAD65 are needed. In addition, it is interesting to explore its potential as tolerogen in the preven-
tion of T1DM13–15.
Isolating GAD65 in high amounts from animal tissues is almost impracticable; therefore, the enzyme should 
be obtained as a recombinant protein. Native GAD65 can be produced in baculovirus-infected Sf9 cells16,17, how-
ever, its expression in baculovirus-infected larvae has not been reported.
The baculovirus-insect expression system is highly chosen when there is a need to express eukaryotic pro-
teins taking into account their native environment. This almost occurs when the desired protein is destined to 
biological or pharmaceutical purposes18. However, the production of recombinant proteins in insect cell culture 
has a big disadvantage: industrial scale production has high costs19. As an alternative, the use of insect larvae as 
bio-factories for the production of recombinant proteins is a more economic strategy, mainly because the need of 
tissue-culture specialized facilities is minimal20,21. The order Lepidoptera (butterflies and moths) is a large group 
of insects comprising more than 100,000 species. Spodoptera frugiperda (S. frugiperda) and Rachiplusia nu (R. nu) 
are two of the most abundant and widely distributed lepidopteran species in Argentina.
In this report, we describe the production of human GAD65 using a baculovirus expression system in two species 
of larvae, R. nu and S. frugiperda. Our aim was to obtain large quantities of properly folded and immunochemically 
active human GAD65 to be used in the development of immunochemical tests for the screening of autoimmune 
diabetes.
Material and Methods
Materials and reagents. Sf900II insect tissue culture media, the S. frugiperda Sf9 cell line, Cellfectin® 
and penicillin/streptomycin (ATB/ATM) were from Invitrogen Life Technologies (Gaithersburg, MD, USA). 
Larvae were obtained from AgIdea S. A. (Pergamino, Buenos Aires, Argentina). Fetal bovine serum (FBS) was 
from Internegocios (Buenos Aires, Argentina). Autographa californica nuclear polyhedrosis virus (AcMNPV), 
pAcGP67-B vector, Agarplaque Plus and BaculoGold Bright were from BD Biosciences Pharmingen (San Diego, 
CA, USA). Disposable materials were from Nunc International (Naperville, IL, USA). The Low Molecular Weight 
Calibration kit (14.4–97.0 kDa), used in SDS-PAGEs and western blots, was from GE Healthcare Life Science 
(Chicago, IL, USA). Antibodies against His6 were from BD Biosciences Pharmingen (San Diego, CA, USA). 
Monoclonal antibodies to GAD65 (GAD6) were obtained from the supernatant of a hybridoma cell culture pur-
chased from the Developmental Studies Hybridoma Bank. Peroxidase-conjugated goat antibodies to mouse IgG 
were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). Other reagents were of analytical 
grade.
Human sera collection. Blood samples were collected from patients after overnight fasting and the cor-
responding sera were stored at −20 °C until assayed. Sera were obtained from selected diabetic patients with a 
wide range of GADA titers. Sera were selected among the samples collected in our laboratory during the routine 
detection of autoantibodies (Servicios Tecnológicos de Alto Nivel, STAN-CONICET).
Control sera were obtained from 56 healthy subjects without personal or family history of autoimmune 
disease. This work was performed with the approval of the Ethical Committee of José de San Martín Clinical 
Hospital, Buenos Aires, Argentina.
All experiments were done in accordance with the relevant guidelines and regulations.
Written informed consent was obtained from all participants.
Virus production. The cDNA encoding the full-length human GAD65 bearing a histidine-hexapeptide 
(His6) tail at the N-terminus (synthesized by GenScript Corporation, Piscataway, NJ, USA; www.GenScript.com) 
was directly cloned into the pAcGP67-B transfer vector downstream the baculovirus polyhedrin promoter and 
the gp67 viral signal peptide sequence, which targets the recombinant protein for secretion (pAcHis6-GAD65). 
One million Sf9 cells were co-transfected with 0.25 μg pAcHis6-GAD65 and 1 μg linearized BaculoGold Bright 
DNA in the presence of Cellfectin® according to standard baculovirus protocols22,23. BaculoGold Bright DNA 
contains the GFP gene. After a 4-day incubation at 27 °C, the cell culture supernatant was collected and centri-
fuged at 3,000 × g for 10 min. The co-transfection efficiency was determined by measuring the GFP expression 
under UV light. The recombinant baculovirus was named AcHis6-GAD65. After 4 days of infection, supernatants 
of co-transfection were used to infect monolayer cultures at a multiplicity of infection (MOI) of 0.02 (first ampli-
fication step of the viral stock). This first amplification supernatant was used to perform the second amplifica-
tion. After three amplification steps, the virus titer was determined by a plaque assay (8.6 × 107 pfu/mL)23. This 
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amplified virus stock was used for the production of the recombinant protein in further experiments. Baculovirus 
was stored at 4 °C until used for the expression of human GAD65 in insect cells and larvae.
Insect cells and larvae. Sf9 cell suspension cultures were grown in sterile Erlenmeyer flasks under con-
tinuous shaking at 100 × g in Sf900II medium supplemented with 1% (v/v) fetal bovine serum (FBS) and 1% 
antibiotic-antimycotic solution at 27 °C. All assays were carried out using Sf9 cells from suspension cultures in 
log-phase growth with 95–99% viability. R. nu and S. frugiperda larvae were obtained from a laboratory colony 
and reared individually in standard 6-well plates on an artificial high-wheat germ diet24 at 23–25 °C in a 70% 
humidified chamber, with a 16:8 h light/dark photoperiod.
Controls were done with either non-infected cells and larvae, or with cells and larvae infected with baculovi-
rus expressing only the GFP.
Recombinant GAD65 expression and purification from cell cultures. The expression of GAD65 
was first evaluated at different MOI (0.5, 1, 2, 4 and 8 pfu per cell) on 6 × 105 Sf9 cells/mL. After infection, cells 
were incubated in the dark at 27 °C. To study the expression among the different days post-infection (dpi), 1 mL 
samples were collected each day until 7 dpi. Culture supernatants were separated from the cells by centrifugation 
at 10,000 × g for 10 min. Sedimented cells and supernatants were then analyzed by SDS-PAGE and WB with mon-
oclonal antibodies against GAD65 (GAD6). The best expression conditions were selected.
The expression of GAD65 was performed at a MOI = 0.5 on 2 × 106 Sf9 cells/mL. Infections were incubated 
in the dark at 27 °C for 4 days and cells were collected by centrifugation at 10,000 × g for 10 min. Sedimented 
cells were resuspended in 1 mL of lysis buffer (20 mMTris/HCl, pH 7.4) and sonicated over crushed ice in the 
presence of 0.05 M EDTA, protease inhibitors (0.1% w/v aprotinin and 2 mM phenylmethylsulfonylfluoride –
PMSF-), 100 mM 2-aminoethyl isothiouronium bromide –AET- an antioxidant agent, and 0.2 mM pyridoxal 
5-phosphate –PLP- GAD65 cofactor. After sonication, Triton-X 100 was added to a final concentration of 1% v/v 
and incubated for 15 min at 0 °C under constant shaking. The soluble intracellular fraction was then separated by 
centrifugation at 20,000 × g for 30 min. The supernatant was adjusted to 20 mM NaH2PO4, pH 8, 0.5 M NaCl and 
then directly applied onto a chelating Sepharose-FF column charged with nickel ions. After 1 h incubation at 4 °C, 
the suspension was poured into a 1.5 cm × 5.0 cm column and washed twice with 2 mL of 20 mM NaH2PO4, pH 8, 
0.5 M NaCl. The recombinant GAD65 protein was eluted with 500 mM imidazole and then stored with a mixture 
of 50% v/v glycerol, 0.2 mM PLP, 0.05% v/v Tween 20 and 0.1% w/v aprotinin.
Recombinant GAD65 expression and purification from larvae. Larvae of R. nu and S. frugiperda 
were injected into the hemocele with 50 μL recombinant baculovirus (107 pfu/mL). Control larvae were either 
uninfected or infected with another baculovirus expressing GFP. Once infected, they were incubated at 24 °C.
For all experiments, fifth-instar larvae were sedated by incubation on ice for 5 min before injection.
Four days after infection, larvae were harvested and their weights determined before individual homogeni-
zation in the presence of 1 mL of lysis buffer per larva (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% 
NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) using a mortar and pestle, and sonicated in the 
presence of protease inhibitors (0.1% v/v aprotinin and 2 mM PMSF), 100 mM AET, 0.2 mM PLP and 1 mM 
DTT. After sonication, Triton X-100 was added to a final concentration of 5%, and the mixture was incubated 
for 30 min at 4 °C under constant shaking. The soluble fraction was separated by centrifugation at 12,000 × g for 
30 min at 4 °C.
The larvae soluble fraction was adjusted to 20 mM NaH2PO4, pH 8, 0.5 M NaCl and 50 mM imidazole by 
exclusion chromatography and then directly applied into a chelating Sepharose-FF column charged with nickel 
ions. After 1 h incubation at 4 °C, the suspension was poured into a 1.5 cm × 5.0 cm column and washed twice 
with 2 mL of 20 mM NaH2PO4, pH 8, 0.5 M NaCl and 50 mM imidazole. Bound proteins were eluted with 5 vol 
elution buffer (20 mM NaH2PO4, pH 8, 0.5 M NaCl, 500 mM imidazole). Purified proteins were stored at −20 °C 
with a mixture of 50% v/v glycerol, 0.2 mM PLP, 0.05% v/v Tween 20 and 0.1% w/v aprotinin.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis. 
Protein fractions were separated by 10% SDS-PAGE under reducing conditions, followed by Coomassie Brilliant 
Blue R-250 staining25. For detection by WB26, protein bands were transferred onto nitrocellulose membranes 
and unoccupied binding sites were blocked by incubating with 3% w/v skim milk in Tris buffer saline (TBS: 
0.05 M Tris-HCl, 0.15 M NaCl, pH 7.5) for 2 h at room temperature (RT). After 3 washing steps with TBS, mem-
branes were incubated ON at 4 °C with either a monoclonal antibody to GAD65 diluted 1/200 or a monoclonal 
antibody to His6, diluted1/3000 both in 3% w/v skim milk, 0.05% v/v Tween 20 in TBS (TBS-MT), and then 
washed five times with 0.05% v/v Tween 20 in TBS (TBS-T). Bound antibodies were visualized by incubation 
with peroxidase-conjugated goat antibodies to mouse IgG diluted 1/2000 in TBS-MT, followed by the addition of 
α-chloronaphthol (Sigma-Aldrich, Inc., St Louis, MO) and 10 vol. H2O2.
GAD65 enzymatic activity measurement. The detection of the enzymatic activity of GAD65 of selected 
samples was performed by a colorimetric assay in a 96-well microplate27. This method is based on the detection of 
the pH increase due to the consumption of protons occuring as the GAD65-catalyzed reaction proceeds. GAD65 
is a PLP-dependent enzyme that catalyzes the α-decarboxylation of L-glutamatic acid to γ-aminobutyric acid 
(GABA). The decarboxylation of glutamic acid irreversibly incorporates a proton into GABA during CO2 release.
The reaction medium in each well consisted of 200 μL of 50 mM acetate buffer, pH 4.8 containing 70 μM bro-
mocresol green, 1 mM PLP and 4 μL of glutamate (1 M in 50 mM acetate buffer). Ten μL of each sample (between 
0.3 to 0.6 mg/ml of protein) were added to different wells. The plate was quickly placed in a microplate reader 
(Varioskan Lux, Thermo Scientific, Waltham, MA, USA) and shaken for 10 seconds to ensure complete mixing. 
The increase in absorbance at 620 nm was monitored at 40 °C. Optical density values were recorded every 30 s 
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for 10 min. Activities were calculated from the slopes measured in the linear portion of the curve, typically over 
the first 300 s. The total amount of protein in each well was taken into account to calculate specific activity (μmol 
min−1 mg−1). Calculations were done as previously reported27.
Eluates of larvae infected with other baculovirus served as negative controls.
Immunochemical characterization of recombinant GAD65. Production of a [35S]GAD65 tracer. As 
previously described in our earlier work28, with some modifications, the tracer [35S]GAD65 was obtained by in 
vitro transcription/translation of cDNA encoding the human GAD65 using a rabbit reticulocyte lysate system 
(Promega, Madison, WI, USA) in the presence of [35S]-methionine (New England, Nuclear, Boston, MA, USA), 
according to the manufacturer’s instructions. Translation products were diluted in RBA buffer (0.02 M Tris–
HCl, 0.15 M NaCl, pH 7.4, 0.1% v/v Tween 20) and applied to a PD10 column (Pharmacia-LKB Biotechnology, 
Uppsala, Sweden) in order to remove free [35S]-methionine.
Inhibition assay. As previously described in our earlier work29 for another recombinant autoantigen related to 
DM, the ability of GAD65 to compete with human [35S]GAD65 was assessed qualitatively by incubating 2.5 µL 
sera from 8 type 1 diabetic patients with 10,000 cpm of tracer in the presence of 1 μM purified protein, either from 
R. nu, S. frugiperda or Sf9 cells, in a final volume of 60 µL. Twenty six control sera were also analyzed in order 
to establish a cut off value. After ON incubation, 50 μL of 40% v/v proteinA-Sepharose 4B FF (GE Healthcare 
Biosciences, Uppsala, Sweden) in RIA buffer (0.02 M Tris-HCl, 0.15 M NaCl, 0.1% Tween 20, pH 7.4) were added 
and incubated for 2 h at RT on an end-over-end shaker. Subsequently, samples were allowed to settle and the 
supernatants were discarded in order to isolate immunocomplexes. Pellets were washed three times with 200 µL 
of RIA buffer and once with 200 µL of 0.2 M NaCl in RIA buffer. Finally, pellets were suspended in 100 µL of 1% 
SDS and supernatants were carefully transferred to vials for scintillation counting (1 min/tube). Results for each 
sample were calculated as B%.
Radioimmunoassay protocol. Quantitative competition assays were performed by a standard radioimmu-
noassay (RIA), as previously described in our earlier work28. The RIA was carried out by incubating 2.5 µL of 
5 GADA-positive type 1 diabetic patient sera with 10,000 cpm of [35S]GAD65 in the presence of serial concen-
trations (0.62 nM-1.4 µM) of purified R. nu-GAD65 and S. frugiperda-GAD65 in a final volume of 60 µL. The 
following steps of the assay are the same as those described previously for the qualitative assay. Results for each 
sample were calculated as B%. Inhibitory dose-response curves [log (inhibitor) vs. response - Variable slope (four 
parameters)] were fitted to the mathematical function:
= + − + − ∗B/B B/B (B/B B/B )/(1 10 )0 0 min 0 max 0 min
[(logIC50 logHis GAD 65 dose) Hill Slope]6
where B corresponds to B% measurements, B0 is the B% at zero concentration of unlabelled antigen, B/B0min and 
B/B0max are the minimal and maximal response, respectively and the parameter IC50 represents the concentration 
of GAD65 that gave a response half between B/B0min and B/B0max. The Hill slope describes the steepness of the 
family of curves.
S. frugiperda-GAD65 application in immunoassay for the detection of GADA. The coating 
buffer was PBS, the blocking buffer was 2% w/v skim milk in PBS, the washing buffer was PBS containing 0.05% 
v/v Tween 20 (PBS-T). Reagent dilutions were prepared in 2% w/v skim milk in PBS-T (PBS-MT). Avidin–
Horseradish Peroxidase (HRP) was purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, 
PA, USA). The 3,3′,5,5′-tetramethyl-benzidine/H2O2 mixture (Single Component TMB Peroxidase EIA Substrate 
Kit, BioRad, Hercules, CA, USA) was employed as the chromogenic substrate. Except otherwise indicated, incu-
bations were performed at RT, washing steps were performed with PBS-T and 50 μL per well were added in each 
incubation step.
Biotinylation of S. frugiperda-GAD65. Two mL of the purified S. frugiperda-GAD65 were subjected to buffer 
exchange to PBS using a ZEBA desalt spin column (Pierce Biotechnology, Rockford, IL, USA) according to the 
manufacturer’s instructions. The desalted protein was then incubated for 2 h at 0 °C with a 20-fold molar excess of 
sulfo-NHS-biotin (Pierce Biotechnology, Rockford, IL, USA). The free biotin was removed using another ZEBA 
desalting spin column.
Bridge-ELISA protocol (b-ELISA). The protocol employed was based on that previously described30, with minor 
modifications. Briefly, polystyrene microplates (Maxisorp, NUNC, Rorkilde, Denmark) were coated ON at 4 °C 
with 0.15 µg of purified S. frugiperda-GAD65 per well, washed three times with PBS, blocked for 1.5 h with 200 µL 
of blocking solution per well, and washed five times. Samples were added in duplicate and microplates were incu-
bated for 1 h. Plates were then washed five times and 22.0 ng of S. frugiperda-GAD65-biotin per well were added. 
After another1 h incubation period, plates were washed five times and the bound S. frugiperda-GAD65-biotin 
was detected by the addition of Avidin-HRP diluted 1/2000. After 1 h incubation, microplates were washed five 
times plus one final washing step with 200 μL of PBS. The chromogenic substrate was then added and plates were 
incubated in the dark. The color reaction was stopped with 4N H2SO4.
Statistical analysis. The same as described in Guerra et al.28, the immunochemical identities and parallel-
ism between inhibitory dose-response curves obtained with Sf9-GAD65, R. nu-GAD65 and S. frugiperda-GAD65 
were analyzed by comparing B/B0min, B/B0max, Hill slope and IC50 values using the extra sum-of-squares F test 
comparison method. The statistical significance when comparing IC50 was determined using the Mann-Whitney 
U-test. The normal distribution of data was assessed by the D’Agostino and Pearson omnibus normality test. In 
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order to remove outliers from normally distributed healthy control individuals, the Rout test was performed. The 
performance of the b-ELISA was analyzed by determining the area under the curve (AUC) of receiver operating 
characteristic (ROC) curves. The Spearman coefficient (rs) was calculated to evaluate the inter-assay correlation. 
The kappa index was used to measure the [strength of agreement] = concordance between the b-ELISA and RBA. 
A kappa value of 0.01–0.20 was indicative of slight agreement; 0.21–0.40, fair agreement; 0.41-0.60, moderate 
agreement; 0.61–0.80, substantial agreement; and 0.81–1.00, almost perfect or perfect agreement31–34.
All calculations were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, San 
Diego, CA, USA, www.graphpad.com). A p value < 0.05 was considered statistically significant.
Results
Expression of Human GAD65 in Sf9 Insect Cells. The recombinant human GAD65 was expressed in 
Sf9 cells. Efficient Sf9-GAD65 production was achieved after 4 days of infection, yielding 3.60 mg of 95% pure 
GAD65/L culture medium. SDS-PAGE and WB analyses of total cell lysates and the different purification steps 
(Fig. 1A,B), with monoclonal specific antibodies to His6, showed one band with the expected molecular weight 
(~66 kDa) for the full-length engineered protein. The identity of the protein was confirmed by WB after incuba-
tion with monoclonal antibodies to GAD65 (GAD6).
Despite having the gp67 signal peptide, the expressed protein was not efficiently exported to the supernatant, 
but remained inside the cells. Consequently, different lysis protocols were tested to achieve a suitable recovery of 
native GAD65 in the supernatants.
Expression of Recombinant Human GAD65 in Insect Larvae. Recombinant AcHis6-GAD65 bac-
ulovirus was also used to infect insect larvae. R. nu and S. frugiperda were infected by intrahemocele injection 
with 50 μL of 107 pfu/mL. After 4 days of infection, both species of larvae were able to express GAD65 with 
Figure 1. Expression and purification of GAD65. Expression and purification in Sf9-cells (A,B), in R. nu 
(C,D) and in S. frugiperda (E,F). (A,C,E) SDS-PAGE (10.0% T 6.0% C, 1.5 mm, under reducing conditions, 
stained with Coomassie Brilliant Blue R-250); (B,D,F) WB revealed with monoclonal antibodies to either His6 
or GAD65 as primary antibody. (A,C,E) Samples: 1. Total soluble fraction, 2. Unbound material, 3. Wash step, 
4–7. Consecutive eluates of purified GAD65. (B,D,F) Samples: 1. Total soluble fraction, 2. Unbound material, 
3. Wash step, 4–6. Consecutive eluates of purified GAD65. Arrows indicate the electrophoretic mobility of 
GAD65. Full-length WB are presented in Supplementary Fig. 1.
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the expected molecular weight of 66 kDa, as demonstrated by SDS-PAGE and WB analyses (Fig. 1C,D for R. 
nu-GAD65, and Fig. 1E,F for S. frugiperda-GAD65). GAD65 was efficiently extracted using a lysis buffer contain-
ing a mixture of ionic and non-ionic detergents. The expression levels of GAD65 in R. nu larvae was 1.06 mg of 
protein per g of larva, with 95% of purity, according to a densitometric analysis; while in S. frugiperda larvae, the 
expression of GAD65 reached 5.70 mg of protein per g of larva with 97% of purity.
Enzymatic Activity. In order to demonstrate that the structure of recombinant human GAD65 expressed by 
baculovirus insect larvae was correctly folded, at least in the proximity of the catalytic site, the enzymatic activity 
was determined by measuring the change in color of bromocresol green, from green to blue. This color change 
is proportional to the pH increase that occurs as GAD65 catalyzes the α-decarboxylation of L-glutamic acid to 
GABA by consuming protons of the reaction medium. R. nu-GAD65 and S. frugiperda-GAD65 exhibited a spe-
cific activity of 190 and 72.8 μmol min−1 mg−1, respectively. Recombinant GAD fused to thioredoxin (TrxGAD)35 
expressed in E. coli was used as a standard protein obtaining an enzymatic activity value of 96 μmol min−1 mg−1. 
All these data confirm that the active site of recombinant GAD65 was correctly folded.
Immunochemical Characterization of Recombinant GAD65. To test the ability of R. nu-GAD65 and 
S. frugiperda-GAD65 to react with GADA, radiocompetition assays were performed. Sera from 8 type 1diabetic 
patients that scored positive by RBA were used. All sera tested were GADA-positive with a B% that ranged from 
9.12% to 37.56%. In addition, 26 control sera from healthy subjects were used to determine a cut off value (B% 
5.03%) and to rule out interferences generated by the sample matrix. The assay was carried out in parallel in the 
presence of ~1 μM GAD65 from R. nu, S. frugiperda and Sf9, for comparison. All 8 positive sera became virtually 
negative under this condition of cold antigen excess, with a B% range from 1.43% to 13.99%, 2.86% to 6.87% and 
1.03% to 5.62%, respectively (Fig. 2). These assays showed that R. nu-GAD65 and S. frugiperda-GAD65, as well as 
Sf9-GAD65, inhibit the binding of GADA to [ 35S]GAD65.
In order to study the immunochemical behavior of GAD65 obtained from larvae, dose-response curves with 
5 sera from GADA-positive diabetic patients were performed by RIA, using [35S]GAD65 as tracer and varia-
ble concentrations of R. nu-GAD65 and S. frugiperda-GAD65 (Fig. 3). All dose-response curves (B/B0 vs. log 
[GAD65]) demonstrated comparable GAD65 immunoreactivities with sera. The GAD65 concentration that 
caused 50% inhibition (IC50) was calculated for each serum. This concentration was similar for 4 out of the 5 
sera analyzed, ranging from 1.07 × 10−7 M to 7.21 × 10−9 M. These values are comparable to those reported for 
pure TrxGAD produced in E. coli35 and to the value estimated for pure GAD65 previously produced in Sf9 insect 
cells17. In addition, no significant differences were found between the values obtained from R. nu-GAD65 and 
S. frugiperda-GAD65 (p < 0.05). These data suggest that the recombinant protein expressed in both larvae are 
immunochemically identical.
Figure 2. Inhibition capacity of GAD65 in the RBA of 8 GADA positive sera. (A) Binding of [35S]GAD65 to 26 
control human sera, (B) binding to GADA-positive sera, (C) binding to GADA-positive sera in the presence of 
1 μM of Sf9-GAD65, (D) binding to GADA-positive sera in the presence of 1 μM of R. nu-GAD65, (E) binding 
to GADA-positive sera in the presence of 1 μM of S. frugiperda-GAD65. Binding is expressed as bound % (B%), 
the cut-off value is shown as a dotted line.
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Detection of GADA by ELISA using S. frugiperda-GAD65. Forty four patient sera displaying a wide 
range of GADA titers were tested in parallel by RBA and bridge-ELISA (b-ELISA) for the detection of GADA. 
The specificity was calculated as 100% minus the percentage of false positives (obtained with healthy control indi-
viduals, n = 56). In order to obtain normally distributed values for healthy control individuals, an outlier removal 
was needed (Rout test, Q = 1%); however, these outliers were included in all plots and in specificity calculations, 
as they were considered false positives. When analyzed by RBA, a median SDs of 14.25 was obtained for the 44 
diabetic patients sera analyzed, ranging from 3.04 to 28.21; cut-off value for positivity SDs = 3.0 (Fig. 4A and 
Figure 3. Quantitative competition radioimmunoassays performed with 5 GADA-positive sera. R. nu-GAD65 
(closed circle) and S. frugiperda-GAD65 (open circle) were used as alternative competitors to displace the [35S]
GAD65 tracer.
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Table 1). With this analysis, a specificity of 96.4% was obtained and healthy control individuals differed signifi-
cantly from diabetic patients (p < 0.0001).
Out of the 44 diabetic GADA-positive patients by RBA, 34 (77.3%) were positive by b-ELISA, with SDs rang-
ing from −1.21 to 84.47 and a median of 9.55; with a cut-off value for positivity SDs = 3.0. These results indicated 
that b-ELISA had an analytical sensitivity of 77.3% for this sera collection (percentage of patients RBA posi-
tive that were positive by b-ELISA) and 98.2% specificity (Fig. 4B and Table 1). In addition, the dynamic range 
of b-ELISA was significantly wider than that of RBA. Despite the differences in the physical–chemical princi-
ples of both techniques, a significant correlation was found between them (Spearman’s coefficient, rs = 0.5850; 
p < 0.0001). Figure 4C shows a statistical comparison of RBA and b-ELISA from diabetic patients and control 
healthy individuals; the concordance between the two immunoassays was 96.7%, with a kappa statistic of 0.9302, 
representing an excellent agreement. Moreover, the performance of b-ELISA was analyzed using ROC analysis, 
obtaining an AUC of 0.8904 (Fig. 4D).
Figure 4. Immunoassays for the assessment of GADA in healthy control and type 1 diabetic patients’ sera. 
Results, expressed as SDs, were obtained by RBA (A) and b-ELISA (B). The cut-off value for each assay is 
indicated as a dotted line and medians for each population are indicated as a full line (****p < 0.0001). (C) 
Correlation analysis for the detection of GADA by RBA and b-ELISA, rs is included. (D) ROC curve analysis of 
b-ELISA, AUC is included.
Median 
(SDs) Range (SDs) Specificitya (%) Analytical Sensitivityb (%)
RBA 14.25 3.04–28.21 96.4 —
b-ELISA 9.55 −(1.21)–84.47 98.2 77.3
Table 1. Analytical parameters of RBA and b-ELISA. a100 minus the percentage of false positives. bPercentage 
of patients RBA positive that were positive by b-ELISA.
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Discussion
Glutamic acid decarboxylase is a major autoantigen in autoimmune DM. The presence of specific autoantibodies 
(GADA) in diabetic patients and the population at risk is the serological evidence of a silent autoimmune process 
against pancreatic beta cells. This feature turns GADA into a promising humoral immune marker for autoim-
mune DM. GADA is one of the earliest detectable islet cell autoantibodies, and is considered highly predictive for 
the development of autoimmune DM36–38. As DM is a slow progress disease, remaining asymptomatic for a long 
preclinical period, serological testing is of importance to establish a preventive treatment.
RBA is the reference method for the detection of GADA. Yet, this method is costly, time-consuming and 
environmentally harmful. For these reasons, non-radiometric methods that are easy to implement for large-scale 
screening should be developed. To that end, production laboratories should rely on a source of properly folded 
human GAD65.
There is a very wide range repertoire of expression systems available for the production of foreign recom-
binant proteins, such as bacterial, yeast, insect and mammalian cells. The choice of the best expression system 
for a particular protein is related to the yield and the biological or immunochemical activity of the recombinant 
protein produced. Herein, we report the production of recombinant human GAD65 in insect larvae using the 
baculovirus expression system. Although GAD65 has been successfully expressed in insect cells cultures, the 
enzyme was obtained with low yields and purity16,17,39. This is the first report on the production of properly folded 
GAD65 in Lepidoptera larvae. The production system presented herein afforded to obtain high yields and purity. 
The baculovirus expression system has proved to be a very powerful system for the production of large quantities 
of biologically active proteins. Besides, this system does not present the drawbacks related to prokaryotic expres-
sion systems, such as misfolding and subsequent aggregation to yield inclusion bodies, which turns the protein 
insoluble and of little value in immunochemical tests based on conformational recognition. It is known that the 
baculovirus-mediated expression in Sf9 insect cells renders proteins with the correct post-translational modifica-
tions40. On the other hand, insect larvae have scarcely been employed in the production of recombinant proteins.
In the present work, we describe the expression of full length human GAD65 fused to a histidine hexapeptide 
moiety at the N-terminus, using the baculovirus expression system in two species of larvae. The recombinant 
baculovirus AcHis6-GAD65 was first generated in quantities of roughly108 pfu/mL. Sf9 insect cells were employed 
in the first attempt to express GAD65. As this first approach was successful, insect larvae (R. nu and S. frugiperda) 
were then infected and protein expression analyzed 4 days post-infection. The His6 moiety allowed the purifica-
tion of the recombinant proteins by Ni2+-chelating chromatography. The GAD65 expression level in Sf9 cells was 
3.6 mg/L culture medium, similarly to that reported by Mauch et al.16, while its expression levels were 1.06 mg 
per g of larva and 5.7 mg per g of larva in R. nu and S. frugiperda, respectively. Thus, the expression level reached 
in S. frugiperda was higher than that reached for other recombinant proteins previously produced with the same 
expression system for diagnostic purposes: DomIIIHFBI (4.5 mg per g of larva)41, and InfluenzaA H1N1 neu-
raminidase (1.2 mg per g of larva)42.
The first quality control step for the expressed proteins was the analysis of their enzymatic activity, which 
directly correlates with the acquisition of the native conformation nearby the active site during the biosynthesis 
of the enzyme. It is known that GAD65 catalyzes the α-decarboxylation of L-glutamic acid to render GABA. This 
reaction was evidenced through a colorimetric assay in which the pH of the reaction medium changed due to 
the consumption of protons. As described in the Results section, both recombinant GAD65 from R. nu and S. 
frugiperda showed enzymatic activity, which was expressed as μmol of glutamic acid consumed to generate GABA 
per minute and per mg of protein involved in the reaction. TrxGAD, previously expressed by our laboratory in E. 
coli, was used as positive control in the assay35.
Taking into account the results obtained by SDS-PAGE and WB, together with those of enzymatic activity, it 
can be assumed that, in this system, genuine human GAD65 was obtained. However, considering that most sera 
from diabetic patients only target conformational discontinue epitopes in autoantigens, the native conformation 
of Sf9-GAD65, R. nu-GAD65 and S. frugiperda-GAD65 was also evaluated with 8 GADA positive sera obtained 
from type 1 diabetic patients. All 8 positive sera became virtually negative when incubated in the presence of an 
excess of GAD65 either from Sf9 cells, R. nu or S. frugiperda (Fig. 2). In addition, dose-response curves generated 
by RIA with 5 different GADA positive sera showed similarity between R. nu-GAD65 and S. frugiperda-GAD65 
(Fig. 3), according to the general principles of immunochemical cross-reactivity43. These immunochemical stud-
ies allowed us to demonstrate that the proteins expressed in both larvae species are able to displace the binding of 
radiolabeled GAD65 from GADA, thus confirming the integrity of conformational epitopes in all the recombinant 
antigens produced. As stated above, this is a critical requirement for GADA recognition. It is noteworthy that the 
approximate median Ka values obtained for the 5 sera used in this analysis were in the order of 107 M−1 for both, 
R. nu-GAD65 and S. frugiperda-GAD65, which correlates with reported data (range from 107 to 1011 M−1)44–46. 
No significant differences were found between the Ka values for the recombinant GAD65 expressed in both larvae 
species, suggesting that both enzymes have immunochemical homology.
Full length human GAD65 was successfully expressed as a properly folded protein through a baculovirus 
expression system in two different hosts, R. nu larvae and S. frugiperda larvae. Although the recombinant pro-
teins were obtained with high purity (>95%), and were found to be immunochemically recognized by specific 
autoantibodies, S. frugiperda-GAD65 yielded the highest levels of expression (>5 mg GAD65 per g larva). Thus, 
we decided to evaluate its implementation in the development of low cost immunoassays, such as ELISA for the 
detection of GADA, either to confirm autoimmune diabetes or for detection in routine screening of individuals 
at risk of autoimmune DM. For this purpose, we selected 44 type 1 diabetic patients previously subjected to 
GADA assessment by the reference method RBA, which shows the best sensitivity and specificity parameters in 
international quality controls (such as the Diabetes Autoantibody Standardization Program –DASP- and Islet 
Autoantibody Standarization Program –IASP-). The b-ELISA developed is based on the immobilization of the 
antigen (S. frugiperda-GAD65) to the solid phase, the incubation with the specific autoantibody (crosslinking 
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molecule) and a fluid phase interaction with the biotinylated antigen (S. frugiperda-GAD65-biotin) through the 
available paratope30,47. In this case, the b-ELISA for the detection of GADA presented a wide dynamic range 
(−1.21 to 84.47 SDs), even higher than that described for the reference method (3.04 to 28.21 SDs). The param-
eters of relative sensitivity (77.3%) and specificity (98.2%) were good enough to be used as a first line screening 
method for assessing GADA, and are even higher than those obtained for the same type of test in international 
quality controls (IASP 2015). The thermodynamic principles applied to ELISA and RBA are different; in the latter, 
the antigen-antibody reaction occurs in the liquid phase, at high dilutions and near the equilibrium state, while 
in ELISA, the interaction occurs in a solid phase, in which the amount of immunocomplexes is highly dependent 
on the concentrations of antibodies. Despite these differences, the correlation between both methods was 96.7%, 
with a kappa index of 0.9302, signifying an excellent agreement. Moreover, the AUC value achieved for b-ELISA 
(0.8904) was considered highly acceptable (Fig. 4). It is also important to highlight that the amount of recombi-
nant GAD65 recovered from a single larva is sufficient to perform 100 tests of b-ELISA.
Taken together, the results obtained herein support the applicability of S. frugiperda-GAD65 in the develop-
ment of b-ELISA for routine determination of GADA. Further studies carried out in our laboratory will assess 
this recombinant protein in tolerance assays to evaluate prevention strategies of the disease.
In conclusion, this is the first time that human GAD65 is expressed as a recombinant protein in insect larvae. 
The platform based on S. frugiperda larvae offers several advantages such as obtaining a biologically active and 
properly folded product through a simple and unexpensive method. Moreover, this system allows high mass 
production of GAD65 to be used not only as standard for laboratory research, but also as an antigen for DM 
diagnosis and treatment.
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